Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

The evolutionary origin of the vasopressin/V2-type receptor/aquaporin axis and the urine-concentrating mechanism.

Juul KV.

Endocrine. 2012 Aug;42(1):63-8. doi: 10.1007/s12020-012-9634-y. Epub 2012 Feb 29. Review.

PMID:
22374125
2.

Phylogenetic, ontogenetic, and pathological aspects of the urine-concentrating mechanism.

Kondo Y, Morimoto T, Nishio T, Aslanova UF, Nishino M, Farajov EI, Sugawara N, Kumagai N, Ohsaga A, Maruyama Y, Takahashi S.

Clin Exp Nephrol. 2006 Sep;10(3):165-74. Review.

PMID:
17009073
3.

Downregulation of renal vasopressin V2 receptor and aquaporin-2 expression parallels age-associated defects in urine concentration.

Tian Y, Serino R, Verbalis JG.

Am J Physiol Renal Physiol. 2004 Oct;287(4):F797-805. Epub 2004 Jun 22.

PMID:
15213068
4.

Vasopressin type-2 receptor and aquaporin-2 water channel mutants in nephrogenic diabetes insipidus.

Deen PM, Knoers NV.

Am J Med Sci. 1998 Nov;316(5):300-9. Review.

PMID:
9822112
5.

Integrin-linked kinase regulates tubular aquaporin-2 content and intracellular location: a link between the extracellular matrix and water reabsorption.

Cano-Peñalver JL, Griera M, Serrano I, Rodríguez-Puyol D, Dedhar S, de Frutos S, Rodríguez-Puyol M.

FASEB J. 2014 Aug;28(8):3645-59. doi: 10.1096/fj.13-249250. Epub 2014 May 1.

PMID:
24784577
6.

[From genes to disease: from vasopressin-V2-receptor and aquaporine-2 to nephrogenic diabetes insipidus].

Knoers NV, Deen PM.

Ned Tijdschr Geneeskd. 2000 Dec 9;144(50):2402-4. Review. Dutch.

PMID:
11145096
7.

Cell biological aspects of the vasopressin type-2 receptor and aquaporin 2 water channel in nephrogenic diabetes insipidus.

Robben JH, Knoers NV, Deen PM.

Am J Physiol Renal Physiol. 2006 Aug;291(2):F257-70. Review.

PMID:
16825342
8.

Acute endotoxemia in rats induces down-regulation of V2 vasopressin receptors and aquaporin-2 content in the kidney medulla.

Grinevich V, Knepper MA, Verbalis J, Reyes I, Aguilera G.

Kidney Int. 2004 Jan;65(1):54-62.

9.
10.

Vasopressin-V2 receptor stimulation reduces sodium excretion in healthy humans.

Bankir L, Fernandes S, Bardoux P, Bouby N, Bichet DG.

J Am Soc Nephrol. 2005 Jul;16(7):1920-8. Epub 2005 May 11.

11.

The physiological and pathophysiological functions of renal and extrarenal vasopressin V2 receptors.

Juul KV, Bichet DG, Nielsen S, Nørgaard JP.

Am J Physiol Renal Physiol. 2014 May 1;306(9):F931-40. doi: 10.1152/ajprenal.00604.2013. Epub 2014 Mar 5. Review.

PMID:
24598801
13.
14.

Vasopressin-independent targeting of aquaporin-2 by selective E-prostanoid receptor agonists alleviates nephrogenic diabetes insipidus.

Olesen ET, Rützler MR, Moeller HB, Praetorius HA, Fenton RA.

Proc Natl Acad Sci U S A. 2011 Aug 2;108(31):12949-54. doi: 10.1073/pnas.1104691108. Epub 2011 Jul 18.

15.

Vasopressin-independent regulation of collecting duct aquaporin-2 in food deprivation.

Wilke C, Sheriff S, Soleimani M, Amlal H.

Kidney Int. 2005 Jan;67(1):201-16.

16.

Urine concentrating and diluting ability during aging.

Sands JM.

J Gerontol A Biol Sci Med Sci. 2012 Dec;67(12):1352-7. doi: 10.1093/gerona/gls128. Epub 2012 May 15. Review.

17.

Role of aquaporin-2 gene expression in hyponatremic rats with chronic vasopressin-induced antidiuresis.

Saito T, Higashiyama M, Nagasaka S, Sasaki S, Saito T, Ishikawa SE.

Kidney Int. 2001 Oct;60(4):1266-76.

18.

Molecular pathogenesis of nephrogenic diabetes insipidus.

Nguyen MK, Nielsen S, Kurtz I.

Clin Exp Nephrol. 2003 Mar;7(1):9-17. Review.

PMID:
14586738
19.

Mutations in the vasopressin V2 receptor and aquaporin-2 genes in 12 families with congenital nephrogenic diabetes insipidus.

Vargas-Poussou R, Forestier L, Dautzenberg MD, Niaudet P, Déchaux M, Antignac C.

J Am Soc Nephrol. 1997 Dec;8(12):1855-62.

20.

A selective EP4 PGE2 receptor agonist alleviates disease in a new mouse model of X-linked nephrogenic diabetes insipidus.

Li JH, Chou CL, Li B, Gavrilova O, Eisner C, Schnermann J, Anderson SA, Deng CX, Knepper MA, Wess J.

J Clin Invest. 2009 Oct;119(10):3115-26. doi: 10.1172/JCI39680.

Supplemental Content

Support Center